The publication of a peer-reviewed study in Biomedicines marks a significant step for Oncotelic Therapeutics (OTCQB: OTLC) as it seeks to validate its artificial intelligence approach to drug discovery. The study, published Oct. 23, 2026, details how the company's PDAOAI platform, using its patented Partitioned Literature Aggregation (PLA) algorithm, identified a four-gene prognostic signature in hepatocellular carcinoma (HCC), the most common form of liver cancer. The genes—FKBP1A, EIF4E, RRAGC and PPARGC1A—were linked to patient survival and independently validated in a Japanese cohort of 203 HCC patients. For Oncotelic, the finding is more than a scientific curiosity: it supports patient stratification for clinical trials of Sapu003, an intravenous formulation of everolimus that the company is developing for liver cancer.
The implications extend beyond a single drug candidate. The ability to identify a robust gene signature using AI-driven literature analysis and survival data suggests a faster, more cost-effective path to biomarker discovery. Oncotelic Chief Business Officer Saran Saund presented the research approach during an Oct. 22 keynote at the 22nd Drug Discovery Strategic Summit in California, highlighting the potential of partitioned AI investigations to generate testable biological hypotheses. If such methods prove broadly applicable, they could accelerate the translation of genomic data into clinical tools, a persistent bottleneck in oncology. The company plans to expand PDAOAI toward a target scale of approximately 100 billion biological vectors for genetic and protein research, a scale that could enable more complex queries across cancer types.
Oncotelic also used the announcement to promote its BIO REBOOT initiative, which invites researchers and development teams to submit projects for potential funding and support in validation, formulation, regulatory planning and clinical development, subject to scientific review and available resources. The initiative signals a push to build a pipeline around the PDAOAI platform, potentially positioning Oncotelic as a service provider or collaborator in addition to a drug developer. For investors, the study's publication in a peer-reviewed journal adds a layer of credibility to the company's AI claims, which have become increasingly common in biotech but often lack independent validation. The Japanese cohort validation is a particularly important detail, as it demonstrates the signature's relevance across populations.
The full press release can be accessed at https://ibn.fm/ctJ4J, and ongoing updates are available in the company's newsroom at https://ibn.fm/OTLC. The announcement was distributed through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio at IBN, which provides corporate communications solutions including social media distribution. The study's findings could also inform the broader use of AI in liver cancer research, where treatment options remain limited and biomarkers are urgently needed.
